Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Faria, B (Author) Other; da Costa, MG (Author) Other; Lima, C (Author) Other; Willems, L (Author) Other; Brandwijk, R (Author) Other; Berger, SP (Author) Other; Daha, MR (Author) Other; Pestana M (Author) FMUP; Seelen, MA (Author) Other; Poppelaars, F (Author) Other

Journal

Title: Journal of Nephrology

Vol. 34

Pages: 801-810

ISSN: 1121-8428

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 3 Citations

Scopus - 3 Citations

Other information

Authenticus ID: P-00T-6T3

DOI: 10.1007/s40620-020-00934-7

Abstract (EN): Introduction Various studies have reported the importance of complement regulators in preventing mesothelial damage during peritoneal dialysis (PD). Its assessment, however, is limited in clinical practice due to the lack of easy access to the peritoneal membrane. Recently, a soluble form of the complement regulatory protein CD59 (sCD59) has been described. We therefore aimed to investigate the role of sCD59 in PD. Methods Plasma sCD59 was measured in 48 PD patients, 41 hemodialysis patients, 15 non-dialysis patients with chronic kidney disease and 14 healthy controls by ELISA (Hycult; HK374-02). Additionally, sCD59 and sC5b-9 were assessed in the peritoneal dialysate. Results sCD59 and sC5b-9 were detectable in the peritoneal dialysate of all patients, and marginally correlated (r = 0.27, P = 0.06). Plasma sCD59 levels were significantly higher in PD patients than in patients with chronic kidney disease and healthy controls, but did not differ from hemodialysis patients. During follow-up, 19% of PD patients developed peritoneal membrane failure and 27% of PD patients developed loss of residual renal function. In adjusted models, increased sCD59 levels in the dialysate (HR 3.44, 95% CI 1.04-11.40, P = 0.04) and in plasma (HR 1.08, 95% CI 1.01-1.17, P = 0.04) were independently associated with the occurrence of peritoneal membrane failure. Higher plasma levels of sCD59 were also associated with loss of residual renal function (HR 1.10, 95% CI 1.04-1.17, P < 0.001). Conclusions Our study suggests that sCD59 has potential as a biomarker to predict peritoneal membrane function and loss of residual renal function in PD, thereby offering a tool to improve patient management.

Language: English

Type (Professor's evaluation): Dissemination

No. of pages: 10